The Continuous Positive Airway Pressure Effect on Rho-associated Coiled-coil Containing Kinases Activity.

Sponsor
Chang Gung Memorial Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05014529
Collaborator
(none)
160
1
38
4.2

Study Details

Study Description

Brief Summary

The ROCK (Rho-associated coiled-coil containing kinases) play a critical role in the pathogenesis of cardiovascular diseases and left ventricle hypertrophy (LVH). ROCK activity can be used as a clinical biomarker for the diagnosis and monitoring of cardiovascular disorders. Obstructive sleep apnea (OSA) increase cardiovascular disease and LVH. Continuous positive airway pressure (CPAP) is the standard therapy for OSA. This study investigate the effect of CPAP on ROCK activity and left ventricle mass.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The ROCK were discovered as downstream targets of Ras homologous A and regulate various important cellular functions, including proliferation, migration, adhesion, and apoptosis. They play a critical role in the pathogenesis of cardiovascular diseases, including cardiac fibrosis, hypertrophy, and remodeling. ROCK activity can be detected in human circulating leukocytes and could potentially be used as a clinical biomarker for the diagnosis and monitoring of cardiovascular disorders. It has been proven that higher ROCK activity is present in left ventricle hypertrophy (LVH) patients than those without LVH. Obstructive sleep apnea(OSA) is characterized by recurrent collapse of the pharyngeal airway during sleep that leads to intermittent nocturnal hypoxia, resulting in a broad range of cardiovascular morbidities, including coronary artery disease, heart failure, cardiac arrhythmias, and LVH. Continuous positive airway pressure (CPAP) is the standard therapy for OSA and several studies have shown that it can effectively reduce cardiovascular disease, but the effect of CPAP on left ventricle mass reduction is still uncertain. Previous studies demonstrated that patients with OSA had higher circulatory ROCK activity than those without OSA, but the role of CPAP on ROCK activity is not known. The circulatory leukocyte ROCK activity may be used as a clinical biomarker for cardiovascular disease and ROCK inhibitors may be used in the future as a treatment. OSA and CPAP treatment may also affect ROCK activity, the relationship between CPAP treatment, cardiac hypertrophy, and ROCK activity is important and should be clarified. Therefore, the main purpose of our study is to evaluate the effect of CPAP on ROCK activity and left ventricle mass.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    160 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    The Continuous Positive Airway Pressure Effect on Rho-associated Coiled-coil Containing Kinases Activity and Left Ventricle Mass in Obstructive Sleep Apnea-hypopnea Syndrome.
    Anticipated Study Start Date :
    Oct 1, 2021
    Anticipated Primary Completion Date :
    Jun 1, 2024
    Anticipated Study Completion Date :
    Dec 1, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    Control group

    Polysomography show AHI less than 15 events/h and participants do not receive any intervention include CPAP, oral appliance, or surgery for 6 months.

    OSA without CPAP group

    Polysomography show AHI greater than 15 events/h and participants do not receive any intervention include CPAP, oral appliance, or surgery for 6 months.

    OSA with CPAP group

    Polysomography show AHI greater than 15 events/h and participants receive CPAP more than 6 months.

    Outcome Measures

    Primary Outcome Measures

    1. ROCK activity [Check baseline blood ROCK 1, ROCK 2, and MYTP-1 p/t and follow up these levels in six months later.]

      Compare the change of blood ROCK 1, ROCK 2, and MYTP-1 p/t (The levels of phosphorylated to total myosin light chain phosphatase 1) among those three groups.

    2. Left ventricle mass [Do baseline echocardiography and follow up echocardiography in six months later.]

      Compare the change left ventricle mass index among those three groups.

    Secondary Outcome Measures

    1. Blood pressure [Obtain initial and blood pressure six months later.]

      Compare the blood pressure among those three groups.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    ● Subjects who complete a standard polysomnography study.

    Exclusion Criteria:
    • Patients who have heart failure (as determined by clinical symptoms or signs with elevated brain natriuretic peptide and echocardiography showing structural or functional abnormalities)

    • Coronary artery disease (stress electrocardiography, myocardial scintigraphy, or coronary angiography proven coronary artery lesion)

    • Hypertrophic cardiomyopathy

    • Known infiltrative disease e.g. amyloidosis

    • Chronic kidney disease severe than stage III

    • Ischemic or hemorrhagic stroke

    • Central sleep apnea,

    • Hypoventilation syndrome (TCO2 or artery PaCO2 exceed 50 mmHg)

    • Unstable hemodynamic state

    • Eastern Cooperative Oncology Group Performance Status higher than grade 2

    • Pregnant women will be excluded.

    • Polysomnography exam showing sleep time less than 2 hours

    • Patients who receive surgery or oral appliance during the study period

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sleep center Keelung Taiwan 204

    Sponsors and Collaborators

    • Chang Gung Memorial Hospital

    Investigators

    • Principal Investigator: Sleep center, Chang-Gung Memorial Hospital, Keelung

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Chung-Chieh, Yu, Director of Pulmonary Medicine Division, Chang Gung Memorial Hospital
    ClinicalTrials.gov Identifier:
    NCT05014529
    Other Study ID Numbers:
    • 202009223870
    First Posted:
    Aug 20, 2021
    Last Update Posted:
    Sep 24, 2021
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Chung-Chieh, Yu, Director of Pulmonary Medicine Division, Chang Gung Memorial Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 24, 2021